Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINE THAI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1043224587
CMS profile
1470
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$811.99

35 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $712.00 34
Education $99.99 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
UCB, Inc. $222.00 6
Janssen Biotech, Inc. $151.88 6
Novartis Pharmaceuticals Corporation $141.76 8
Lilly USA, LLC $116.92 4
Amgen Inc. $79.08 5
Organon LLC $29.62 2
Exact Sciences Corporation $20.81 1
Radius Health, Inc. $19.37 1
AstraZeneca Pharmaceuticals LP $15.75 1
ABBVIE INC. $14.80 1

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINE THAI

NPI 1043224587 · CMS profile ID 1470

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043224587?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043224587?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043224587?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1043224587?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

35 matching records · $811.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 35 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–35 of 35.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.4612/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228325922 CMS
UCB, Inc. $39.5612/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224766591 CMS
Novartis Pharmaceuticals Corporation $24.2112/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200430287 CMS
Janssen Biotech, Inc. $17.9611/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174631660 CMS
Amgen Inc. $17.3111/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228325918 CMS
Novartis Pharmaceuticals Corporation $19.6810/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200495976 CMS
UCB, Inc. $31.1510/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224766589 CMS
Novartis Pharmaceuticals Corporation $13.5909/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200495968 CMS
Amgen Inc. $15.4109/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228325920 CMS
Janssen Biotech, Inc. $13.8809/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174631455 CMS
Organon LLC $16.0208/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237642092 CMS
Lilly USA, LLC $28.7608/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186555870 CMS
UCB, Inc. $35.1608/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224766587 CMS
Amgen Inc. $15.8708/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228325924 CMS
AstraZeneca Pharmaceuticals LP $15.7508/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206389562 CMS
Novartis Pharmaceuticals Corporation $14.8108/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200495960 CMS
UCB, Inc. $41.8106/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224766585 CMS
Lilly USA, LLC $29.6006/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186551442 CMS
Janssen Biotech, Inc. $99.9906/06/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1174631445 CMS
Janssen Biotech, Inc. $10.9305/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174631265 CMS
Janssen Biotech, Inc. $4.5005/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174631525 CMS
Janssen Biotech, Inc. $4.6205/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174631849 CMS
Novartis Pharmaceuticals Corporation $24.3905/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200495958 CMS
Lilly USA, LLC $30.7004/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186558886 CMS
ABBVIE INC. $14.8004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204506320 CMS
UCB, Inc. $47.4704/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224766583 CMS
Radius Health, Inc. $19.3704/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249505981 CMS
Novartis Pharmaceuticals Corporation $13.5603/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200495956 CMS
Organon LLC $13.6003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237642090 CMS
UCB, Inc. $26.8503/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224766581 CMS
Exact Sciences Corporation $20.8102/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235649736 CMS
Novartis Pharmaceuticals Corporation $13.5802/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200495948 CMS
Novartis Pharmaceuticals Corporation $17.9401/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200495946 CMS
Lilly USA, LLC $27.8601/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186555596 CMS
Amgen Inc. $14.0301/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227052548 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,357.35 137
PY2020 $1,472.25 78
PY2021 $298.93 19
PY2022 $874.35 56
PY2023 $974.73 69
PY2024 $693.01 43
PY2025 $811.99 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,372,053.89 61
PY2024 Recipient $8,444.46 4
PY2024 Principal investigator $1,430,507.12 79
PY2023 Recipient $8,498.49 1
PY2023 Principal investigator $1,858,436.22 86
PY2022 Recipient $72,841.00 2
PY2022 Principal investigator $1,860,641.35 160
PY2021 Recipient $2,012.04 2
PY2021 Principal investigator $577,779.35 91
PY2020 Recipient $2,580.07 2
PY2020 Principal investigator $908,629.40 110
PY2019 Recipient $16,824.73 4
PY2019 Principal investigator $518,505.93 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

162 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,356.67 12/31/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH HUNTINGTON BE
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889827753
Principal investigator 1 ABBVIE INC. $1,124.64 12/31/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2) No dispute reported 06/30/2026 965540027
Principal investigator 1 Eli Lilly and Company $2,743.00 12/27/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917833765
Principal investigator 1 Janssen Research & Development, LLC $1,324.00 12/26/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 885251559
Principal investigator 1 Janssen Research & Development, LLC $6,369.00 12/20/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251561
Principal investigator 1 ABBVIE INC. $1,640.90 12/15/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889825647
Principal investigator 1 ABBVIE INC. $7,556.00 12/14/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889825159
Principal investigator 1 ABBVIE INC. $25,529.40 12/14/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889825175
Principal investigator 1 ABBVIE INC. $2,206.48 12/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889822667
Principal investigator 1 Janssen Research & Development, LLC $1,467.00 11/28/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 885251555
Principal investigator 1 ABBVIE INC. $1,427.92 11/16/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889820909
Principal investigator 1 Janssen Research & Development, LLC $10,882.00 11/14/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251557
Principal investigator 1 ABBVIE INC. $2,188.56 11/09/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889819277
Principal investigator 1 ABBVIE INC. $7,483.90 11/09/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889819279
Principal investigator 1 ABBVIE INC. $27,617.35 11/09/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889819291
Principal investigator 1 ABBVIE INC. $2,288.38 11/09/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889819301
Principal investigator 1 ABBVIE INC. $2,142.13 11/08/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889818407
Principal investigator 1 Janssen Research & Development, LLC $1,893.00 10/31/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 885251553
Principal investigator 1 Eli Lilly and Company $1,226.00 10/26/2022 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 917826865
Principal investigator 1 ABBVIE INC. $16,845.40 10/13/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889815453
Principal investigator 1 ABBVIE INC. $3,454.88 10/13/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889815459
Principal investigator 1 ABBVIE INC. $3,250.50 10/13/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889816487
Principal investigator 1 ABBVIE INC. $2,206.48 10/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889814433
Principal investigator 1 ABBVIE INC. $1,782.78 10/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889814459
Principal investigator 1 ABBVIE INC. $3,626.64 10/12/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889814535
Principal investigator 1 ABBVIE INC. $765.00 10/06/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889813165
Principal investigator 1 ABBVIE INC. $50.00 10/06/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889813179
Principal investigator 1 ABBVIE INC. $50.00 10/04/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889812931
Principal investigator 1 Janssen Research & Development, LLC $1,636.00 09/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 885251551
Principal investigator 1 ABBVIE INC. $4,823.36 09/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889809621
Principal investigator 1 ABBVIE INC. $3,545.88 09/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889809697
Principal investigator 1 ABBVIE INC. $745.00 09/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889809699
Principal investigator 1 ABBVIE INC. $1,850.00 09/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889810703
Principal investigator 1 ABBVIE INC. $22,374.95 09/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889808361
Principal investigator 1 ABBVIE INC. $1,739.26 09/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889808383
Principal investigator 1 ABBVIE INC. $1,948.00 09/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889808405
Principal investigator 1 ABBVIE INC. $5,565.59 09/07/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889808931
Principal investigator 1 Janssen Research & Development, LLC $23,586.00 09/06/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251549
Principal investigator 1 Eli Lilly and Company $6,936.00 08/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 917833629
Principal investigator 1 ABBVIE INC. $700.00 08/22/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889807347
Principal investigator 1 ABBVIE INC. $1,251.80 08/11/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889805951
Principal investigator 1 ABBVIE INC. $1,896.72 08/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889804151
Principal investigator 1 ABBVIE INC. $241.92 08/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889804153
Principal investigator 1 ABBVIE INC. $3,608.00 08/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889804205
Principal investigator 1 ABBVIE INC. $24,923.60 08/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889804961
Recipient Eli Lilly and Company $279.00 08/08/2022 Covered Recipient Physician A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 917808589
Principal investigator 1 ABBVIE INC. $32,239.35 07/13/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889800399
Principal investigator 1 ABBVIE INC. $4,906.24 07/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 889800063
Principal investigator 1 ABBVIE INC. $2,855.84 07/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889800093
Principal investigator 1 Eli Lilly and Company $8,700.00 07/12/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917830693
Principal investigator 1 ABBVIE INC. $5,470.90 07/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889799369
Principal investigator 1 ABBVIE INC. $2,188.56 07/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889799371
Principal investigator 1 ABBVIE INC. $2,315.26 07/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889799373
Principal investigator 1 ABBVIE INC. $1,976.00 07/07/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889799375
Principal investigator 1 ABBVIE INC. $12,403.00 06/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889797605
Principal investigator 1 ABBVIE INC. $25,606.80 06/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889797607
Principal investigator 1 ABBVIE INC. $27,205.00 06/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889797611
Principal investigator 1 ABBVIE INC. $13,203.00 06/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889797613
Principal investigator 1 ABBVIE INC. $14,002.00 06/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889797615
Principal investigator 1 ABBVIE INC. $38,010.00 06/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889797617
Principal investigator 1 ABBVIE INC. $38,010.00 06/30/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889797619
Principal investigator 1 ABBVIE INC. $300.00 06/30/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889797623
Principal investigator 1 Janssen Research & Development, LLC $5,202.00 06/27/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251545
Principal investigator 1 ABBVIE INC. $100.00 06/16/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889795833
Principal investigator 1 ABBVIE INC. $3,132.32 06/16/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889795835
Principal investigator 1 ABBVIE INC. $2,718.46 06/14/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889795203
Principal investigator 1 ABBVIE INC. $200.00 06/14/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889795209
Principal investigator 1 ABBVIE INC. $28,134.90 06/09/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889794707
Principal investigator 1 ABBVIE INC. $1,984.77 06/07/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889793761
Principal investigator 1 ABBVIE INC. $6,273.84 06/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889793767
Principal investigator 1 Janssen Research & Development, LLC $6,538.00 06/03/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251547
Principal investigator 1 ABBVIE INC. $119.12 06/02/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889793441
Principal investigator 1 ABBVIE INC. $826.80 06/02/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889793443
Principal investigator 1 Eli Lilly and Company $27,448.00 06/01/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 917830699
Principal investigator 1 ABBVIE INC. $500.00 05/20/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889792475
Principal investigator 1 ABBVIE INC. $9,587.86 05/12/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889791527
Principal investigator 1 ABBVIE INC. $1,683.92 05/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889791537
Principal investigator 1 ABBVIE INC. $1,739.26 05/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889791551
Principal investigator 1 ABBVIE INC. $1,896.72 05/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889791553
Principal investigator 1 ABBVIE INC. $31,654.35 05/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889790645
Principal investigator 1 Janssen Research & Development, LLC $9,159.00 05/05/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251543
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 05/02/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 885251541
Principal investigator 1 ABBVIE INC. $200.00 04/27/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889788727
Principal investigator 1 ABBVIE INC. $250.00 04/27/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889788757
Principal investigator 1 ABBVIE INC. $485.12 04/21/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889787703
Principal investigator 1 ABBVIE INC. $50.00 04/21/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889787769
Principal investigator 1 ABBVIE INC. $1,069.00 04/19/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889787283
Principal investigator 1 ABBVIE INC. $1,806.80 04/14/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889785967
Principal investigator 1 ABBVIE INC. $500.00 04/14/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 889786367
Principal investigator 1 ABBVIE INC. $2,188.56 04/07/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889784017
Principal investigator 1 ABBVIE INC. $20,870.85 04/06/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889783651
Principal investigator 1 ABBVIE INC. $200.00 04/05/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889783353
Principal investigator 1 ABBVIE INC. $241.92 04/05/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889783385
Principal investigator 1 ABBVIE INC. $340.12 04/05/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889783485
Principal investigator 1 ABBVIE INC. $5,996.00 03/31/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782861
Principal investigator 1 ABBVIE INC. $560.00 03/31/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782863
Principal investigator 1 ABBVIE INC. $1,520.00 03/31/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782865
Principal investigator 1 ABBVIE INC. $2,850.00 03/31/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889783237
Principal investigator 1 Janssen Research & Development, LLC $5,000.00 03/28/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251535
Principal investigator 1 Janssen Research & Development, LLC $1,880.00 03/28/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251537
Principal investigator 1 ABBVIE INC. $7,192.00 03/23/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782417
Principal investigator 1 ABBVIE INC. $7,192.00 03/23/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782419
Principal investigator 1 ABBVIE INC. $7,192.00 03/23/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782421
Principal investigator 1 ABBVIE INC. $7,192.00 03/23/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782423
Principal investigator 1 ABBVIE INC. $1,650.00 03/22/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782229
Principal investigator 1 ABBVIE INC. $2,850.00 03/22/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782231
Principal investigator 1 ABBVIE INC. $700.00 03/22/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782233
Principal investigator 1 ABBVIE INC. $1,690.00 03/22/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782235
Principal investigator 1 ABBVIE INC. $800.00 03/22/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889782237
Principal investigator 1 ABBVIE INC. $4,835.44 03/17/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889781343
Principal investigator 1 ABBVIE INC. $8,233.20 03/17/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889781455
Principal investigator 1 ABBVIE INC. $4,478.40 03/15/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 No dispute reported 06/30/2026 889780995
Principal investigator 1 ABBVIE INC. $241.92 03/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 889780201
Principal investigator 1 ABBVIE INC. $26.18 03/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889780317
Principal investigator 1 ABBVIE INC. $700.00 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 889779359
Principal investigator 1 ABBVIE INC. $10.84 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779369
Principal investigator 1 ABBVIE INC. $32.53 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779371
Principal investigator 1 ABBVIE INC. $8,808.00 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889779373
Principal investigator 1 ABBVIE INC. $12.09 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779389
Principal investigator 1 ABBVIE INC. $17.54 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779391
Principal investigator 1 ABBVIE INC. $2,609.10 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779461
Principal investigator 1 ABBVIE INC. $24,488.10 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779463
Principal investigator 1 ABBVIE INC. $100.00 03/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889779465
Principal investigator 1 ABBVIE INC. $3,270.40 03/08/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889779889
Principal investigator 1 ABBVIE INC. $5,070.22 03/08/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 889779939
Principal investigator 1 ABBVIE INC. $150.00 03/03/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889779049
Principal investigator 1 Eli Lilly and Company $633.00 03/03/2022 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 917825595
Principal investigator 1 ABBVIE INC. $4.04 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889778679
Principal investigator 1 ABBVIE INC. $3.21 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889778681
Principal investigator 1 ABBVIE INC. $11.71 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889778689
Principal investigator 1 ABBVIE INC. $10.84 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 889778691
Principal investigator 1 ABBVIE INC. $6.42 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889778695
Principal investigator 1 ABBVIE INC. $204.46 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889778697
Principal investigator 1 ABBVIE INC. $8.09 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889778699
Principal investigator 1 ABBVIE INC. $13.08 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889778701
Principal investigator 1 ABBVIE INC. $7.76 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889778703
Principal investigator 1 ABBVIE INC. $8.03 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889778715
Principal investigator 1 ABBVIE INC. $11.71 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889778717
Principal investigator 1 ABBVIE INC. $11.71 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 889778719
Principal investigator 1 ABBVIE INC. $121.00 03/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) No dispute reported 06/30/2026 889778787
Principal investigator 1 Janssen Research & Development, LLC $2,247.00 02/28/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 885251539
Principal investigator 1 ABBVIE INC. $1,367.76 02/16/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889777467
Principal investigator 1 ABBVIE INC. $28,428.40 02/08/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. No dispute reported 06/30/2026 889776099
Principal investigator 1 ABBVIE INC. $2,188.56 02/03/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2) No dispute reported 06/30/2026 889775567
Principal investigator 1 ABBVIE INC. $632.85 02/03/2022 Non-covered Recipient Entity
MERIDIAN INVESTIGATOR NETWORK LLC
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy No dispute reported 06/30/2026 889775569
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,500.00 02/02/2022 Non-covered Recipient Entity
Newport Huntington Medical Group
Phase II Study SLE - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 933191507
Principal investigator 1 Eli Lilly and Company $539.00 02/01/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917819773
Principal investigator 1 Eli Lilly and Company $3,261.00 01/26/2022 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, TWO-ARM, PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917822819
Principal investigator 1 Eli Lilly and Company $1,968.00 01/26/2022 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 917826113
Principal investigator 1 Eli Lilly and Company $1,787.00 01/26/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 917830687
Principal investigator 1 ABBVIE INC. $2,188.56 01/13/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2) No dispute reported 06/30/2026 889774247
Principal investigator 1 ABBVIE INC. $2,895.52 01/12/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs No dispute reported 06/30/2026 889773627
Recipient Eli Lilly and Company $72,562.00 01/11/2022 Covered Recipient Physician A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917809163
Principal investigator 1 Eli Lilly and Company $2,500.00 01/10/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MULTICENTER LONG-TERM EXTENSION STUDY OF 104 WEEKS INCLUDING A DOUBLE BLIND PLACEBO CONTROLLED 40 WEEK RANDOMIZED WITHDRAWAL RETREATMENT PERIOD TO EVALUATE THE MAINTENANCE OF TREATMENT EFFECT OF IXEKIZUMAB LY2439821 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS No dispute reported 06/30/2026 917822333
Principal investigator 1 ABBVIE INC. $32,483.10 01/06/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. No dispute reported 06/30/2026 889772813
Principal investigator 1 ABBVIE INC. $9,227.49 01/06/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2) No dispute reported 06/30/2026 889772815
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,833.00 01/06/2022 Non-covered Recipient Entity
Christine Thai Md
Phase II Study SLE - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BMS-986256 in Participants with Active Systemic Lupus Erythematosus No dispute reported 06/30/2026 933191459
Principal investigator 1 Novartis Pharmaceuticals Corporation $69.36 01/05/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ENSOVIBEP (MP0420) IN AMBULATORY ADULT PATIENTS WITH SYMPTOMATIC COVID-19 No dispute reported 06/30/2026 910070121
Principal investigator 1 Eli Lilly and Company $45,112.00 01/04/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 917832841
Principal investigator 1 Eli Lilly and Company $18,181.00 01/04/2022 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 917833771
Principal investigator 1 Eli Lilly and Company $916,410.00 01/03/2022 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 917822559
Principal investigator 1 Eli Lilly and Company $6,055.00 01/01/2022 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 917820031